Christiaan Mulder is a senior epidemiologist at KNCV with 14 years of experience in TB related research. He holds a PhD in Epidemiology which he obtained at the University of Amsterdam. Prior to joining KNCV, he lived and worked in rural Tanzania to do research on innovative TB diagnostics. At KNCV, he conducts epidemiological, health economic, and qualitative research. He conducts TB epidemiological (in collaboration with WHO) and diagnostic network assessments (in collaboration with USAID and FIND) in high TB-burden countries. He provides technical assistance for the design and implementation of drug resistance surveys and optimal screening and diagnostic algorithms. He serves as the technical lead for the UNITAID funded IMPAACT4TB-project in Ethiopia, Indonesia, Malawi, and Tanzania. He is a co-investigator on TB preventive treatment studies nested in the IMPAACT4TB project, including cluster randomized trials, qualitative, and health economic research components. He has lead TB Alliance funded budget impact analyses on introducing new regimens for drug-resistant TB. He is a co-investigator on UNITAID funded research on optimizing testing strategies for COVID-19. He supports evidence generation for accelerating the use of nanopore targeted sequencing for infectious disease in low-and-middle income countries. Christiaan is supporting countries using the BMGF supported People-Centered Framework (PCF) Approach to optimize TB programming. He is affiliated to the Amsterdam Institute for Global Health and Development (AIGHD), is a member of the scientific advisory committee of APOPO, and was selected by WHO for a technical consultation on innovative clinical trial designs for evaluating new TPT regimens in 2022. He has published 24 peer-reviewed scientific manuscripts and serves as a peer reviewer for several high-impact journals.